Advanced Search

 

Study ID Status Title Patient Level Data
PRO30011 Completed An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor-Experienced Subjects with HIV-1 Infection Who are Failing Their Current Antiretroviral Treatment Regimen.
PRO30012 Completed An Open-Label Study to Evaluate the Safety and Tolerance of Amprenavir (141W94) Combination Therapy in Protease Inhibitor Experienced Subjects Who Are Intolerant (Hyperlipidemia With or Without lipodystrophy) But Not Failing Their Current Protease Inhibitor Therapy
PRO30013 Completed Amprenavir (141W94) Open Label Study for Subjects with HIV infection who are Failing or are Intolerant to Previous Protease Inhibitor Therapy.
PRO30017 Completed A Phase III Randomised Multicentre Open-Label Study to Evaluate the Efficacy of AGENERASE (AGN; 600mg BID) in Combination with Low Dose Ritonavir (RTV; 100mg BID) Versus Other Protease Inhibitors (PIs) in HIV-Infected PI-Experienced Adults Over a 16 Week Period: Final Analyses of PRO30017…
PRO30017_1 Completed A Phase III randomised multicentre open-label study to evaluate the efficacy of AGENERASE (AGN; 600mg BID)/Ritonavir (RTV; 100mg BID) versus continued protease inhibitors (PIs) in HIV-1 Infected PI-experienced adults with evidence of HIV resistance to all approved PIs other than amprenavir: Fina ...
PROA1001 Completed A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 141W94 (Protease Inhibitor).
PROA1002 Completed The Pharmacokinetics and Pharmacodynamics of a Phase I/II Trial to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of Amprenavir After Multiple Dosing in Subjects With HIV InfectionExtensive searching has revealed that no clinical study report is available for this study…
PROA1003 Completed A randomized cross-over study to evaluate the safety and pharmacokinetics of 141W94, zidovudine and lamivudine alone and in combination after single-dose administration in HIV-infected subjects.
PROA1005 Completed A Study to Investigate whether there is a Pharmacokinetic Interaction between 141W94 and Ketoconazole following their Co-Administration to Healthy Male Volunteers.
PROA1006 Completed A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Pharmacokinetics and Tolerability of Single, Oral Doses of 141W94 in HIV-Infected Children.
PROA1007 Completed A mass balance study to investigate the metabolic disposition of a single, oral dose of radiolabelled [14C]-141W94 in healthy male subjects.
PROA1010 Completed A Phase I, Open-label, Randomized, Balanced, Three period, Cross-over Study to Assess the Bioequivalence of a New 150 mg Soft Gelatin 141W94 Capsule With a Reduced TPGS Content Relative to the Original High TPGS Content 150 mg Soft Gelatin Capsule and to Assess the Effect of Food Upon the Oral B ...
PROA1011 Completed A phase I, open-label, randomized, balanced, three period, cross-over study to assess the oral bioavailability of the new 50 and 150 mg soft gelatin capsules relative to the new 141W94 (amprenavir) oral solution in healthy male subjects.
PROA1012 Completed A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 141W94 and Rifabutin and 141W94 and Rifampin Following Their Co-Administration to Healthy Male Volunteers.
PROA1013 Completed A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 141W94 and Clarithromycin Following Their Co-Administration to Healthy Male Volunteers.
PROAB3001 Completed A Phase III Trial to Evaluate the Safety and Antiviral Efficacy of 141W94 in Combination with RETROVIR and EPIVIR Compared to RETROVIR and EPIVIR Alone in Patients with HIV Infection.
PROAB3004 Completed A Phase III, Open Label Trial to Evaluate the Safety, Antiviral Efficacy and Pharmacokinetics of 141W94 Plus Current Therapy in HIV-1 Infected Children.
PROAB3006 Completed A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 with Indinavir in Combination with Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy in NRTI Experienced, Protease Inhibitor (PI) Naïve HIV-1 Infected Patients
PROAB3007 Completed An open-label phase III study to assess the long term safety profile of amprenavir (141W94) containing regimens in HIV infected subjects
PROB1008 Completed A study to compare the pharmacokinetics of a single, oral, 600mg dose of amprenavir in healthy volunteers and patients with cirrhosis.
PROB2004 Completed A Phase II Trial to Assess the Preliminary Antiviral Effect, Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of APV Oral Solution in Combination with NRTIs in HIV Infected Children Below 13 Years Old
PROF3002 Completed Open label pilot study to evaluate the effect of antiretroviral drugs on HIV-1 in different compartments (plasma and lymphoid tissues).
R1810198 Completed An actual use study in support of the over-the-counter switch of Flonase Allergy
R1810220 Completed An efficacy and safety study of fluticasone propionate (FP) aqueous nasal spray in subjects with perennial allergic rhinitis (PAR)
R1810221 Completed An efficacy and safety study of fluticasone propionate (FP) aqueous nasal spray in subjects with seasonal allergic rhinitis (SAR)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.